125 related articles for article (PubMed ID: 8549368)
1. Laboratory and clinical study of T-3761, a new fluoroquinolone, in urinary tract infection.
Suzuki K; Horiba Y; Ishikawa K; Katoh S; Naide Y; Yanaoka L; Andoh S
Drugs; 1995; 49 Suppl 2():379-81. PubMed ID: 8549368
[No Abstract] [Full Text] [Related]
2. Laboratory and clinical study of balofloxacin (Q-35), a new fluoroquinolone, in urinary tract infection.
Suzuki K; Horiba M; Ishikawa K; Katoh S; Naide Y; Yanaoka M; Andoh S
Drugs; 1995; 49 Suppl 2():376-8. PubMed ID: 8549367
[No Abstract] [Full Text] [Related]
3. In vivo selection of Pseudomonas Aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection.
Nakano M; Yasuda M; Yokoi S; Takahashi Y; Ishihara S; Deguchi T
Urology; 2001 Jul; 58(1):125-8. PubMed ID: 11445503
[TBL] [Abstract][Full Text] [Related]
4. Clinical study of T-3761 in obstetrics and gynaecology.
Matsuda S
Drugs; 1995; 49 Suppl 2():393-4. PubMed ID: 8549374
[No Abstract] [Full Text] [Related]
5. Two new fluoroquinolones.
Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
[No Abstract] [Full Text] [Related]
6. Pharmacology of the fluoroquinolones.
Scully BE
Urology; 1990 Jan; 35(1 Suppl):8-10. PubMed ID: 2404373
[No Abstract] [Full Text] [Related]
7. Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: a national cross-sectional study.
Hwang TJ; Hooper DC
J Antimicrob Chemother; 2014 Jun; 69(6):1720-2. PubMed ID: 24521853
[No Abstract] [Full Text] [Related]
8. Which fluoroquinolones are suitable for the treatment of urinary tract infections?
Naber KG
Int J Antimicrob Agents; 2001 Apr; 17(4):331-41. PubMed ID: 11295418
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and clinical studies of T-3761 in otorhinolaryngeal infections.
Shinkawa A; Kimura H; Sakai M; Miyake H
Drugs; 1995; 49 Suppl 2():401-2. PubMed ID: 8549377
[No Abstract] [Full Text] [Related]
10. [The use of Maxaquin (lomefloxacin hydrochloride) in the treatment of nonspecific inflammatory diseases and in the prevention of surgical interventions in urology].
Derevianko II; Lopatkin NA; Khodyreva LA; Kondrat'eva EM
Urol Nefrol (Mosk); 1998; (5):14-8. PubMed ID: 9820038
[No Abstract] [Full Text] [Related]
11. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
12. USA resistance patterns among UTI pathogens.
Thomson KS; Sanders WE; Sanders CC
J Antimicrob Chemother; 1994 May; 33 Suppl A():9-15. PubMed ID: 7928840
[TBL] [Abstract][Full Text] [Related]
13. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
Yoshizumi S; Takahashi Y; Murata M; Domon H; Furuya N; Ishii Y; Matsumoto T; Ohno A; Tateda K; Miyazaki S; Yamaguchi K
J Antimicrob Chemother; 2001 Jul; 48(1):137-40. PubMed ID: 11418525
[TBL] [Abstract][Full Text] [Related]
14. [New fluoroquinolones in urology].
Derevianko II; Hefedova LA
Urologiia; 2004; (4):27-32. PubMed ID: 15457949
[TBL] [Abstract][Full Text] [Related]
15. Open randomised comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections.
Rugendorff EW
Drugs; 1987; 34 Suppl 1():91-4. PubMed ID: 3481333
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
Mikuniya T; Kato Y; Ida T; Maebashi K; Monden K; Kariyama R; Kumon H
J Infect Chemother; 2007 Oct; 13(5):285-90. PubMed ID: 17982715
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ciprofloxacin nonsusceptible urinary tract infections with ciprofloxacin.
Jeffres MN; Shuster JE; Barclay SM
Ann Pharmacother; 2011 Jun; 45(6):824-5. PubMed ID: 21666093
[No Abstract] [Full Text] [Related]
18. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
Martin SJ; Jung R; Garvin CG
Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolones.
Molavi A
Am Fam Physician; 1988 May; 37(5):279-84. PubMed ID: 3284309
[No Abstract] [Full Text] [Related]
20. Application of ofloxacin in gynaecology.
Petersen EE; de Isele TS; Pelz K; Weiss N
Drugs; 1987; 34 Suppl 1():183-6. PubMed ID: 3481322
[No Abstract] [Full Text] [Related]
[Next] [New Search]
